Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 152

1.

C-reactive protein and angiographic characteristics of stable and unstable coronary artery disease: data from the prospective PREVEND cohort.

Geluk CA, Post WJ, Hillege HL, Tio RA, Tijssen JG, van Dijk RB, Dijk WA, Bakker SJ, de Jong PE, van Gilst WH, Zijlstra F.

Atherosclerosis. 2008 Jan;196(1):372-82.

PMID:
17157301
2.

C-reactive protein associated with coronary artery disease in Iranian patients with angiographically defined coronary artery disease.

Kazemi-Bajestani SM, Ghayour-Mobarhan M, Ebrahimi M, Moohebati M, Esmaeili HA, Ferns GA.

Clin Lab. 2007;53(1-2):49-56.

PMID:
17323825
3.

[Clinical characteristics of coronary artery disease patients with reduced left ventricular ejection fraction and their prognostic analysis].

Li Q, Gao YC, He JQ, Jiang TY, Ren XJ, Chen F.

Zhongguo Wei Zhong Bing Ji Jiu Yi Xue. 2012 Dec;24(12):734-8. Chinese.

4.

Prognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease.

Sabatine MS, Morrow DA, Jablonski KA, Rice MM, Warnica JW, Domanski MJ, Hsia J, Gersh BJ, Rifai N, Ridker PM, Pfeffer MA, Braunwald E; PEACE Investigators..

Circulation. 2007 Mar 27;115(12):1528-36.

5.

[Predictive value of fibrinogen and high-sensitivity C-reaction protein for cardiovascular events in patients with stable coronary artery disease].

Huang W, Chen QW, Lei H, Deng W, Ke DZ.

Zhonghua Xin Xue Guan Bing Za Zhi. 2006 Aug;34(8):718-21. Chinese.

PMID:
17081398
6.
7.
8.
9.

Inflammatory markers, angiographic severity of coronary artery disease, and patient outcome.

Sukhija R, Fahdi I, Garza L, Fink L, Scott M, Aude W, Pacheco R, Bursac Z, Grant A, Mehta JL.

Am J Cardiol. 2007 Apr 1;99(7):879-84.

PMID:
17398176
10.

Increased plasma C-reactive protein level predicts rapid progression of non-target atherosclerotic lesions in patients with stable angina after stenting.

Xu YL, Li JJ, Xu B, Zhu CG, Yang YJ, Chen JL, Qiao SB, Yuan JQ, Qin XW, Ma WH, Yao M, Liu HB, Wu YJ, Chen J, You SJ, Dai J, Xia R, Gao RL.

Chin Med J (Engl). 2011 Oct;124(19):3022-9.

11.

Time-dependent changes of hs-CRP serum concentration in patients with non-ST elevation acute coronary syndrome.

Jahn J, Hellmann I, Maass M, Giannitsis E, Dalhoff K, Katus HA.

Herz. 2004 Dec;29(8):795-801.

PMID:
15599677
12.

Coronary severity score and C-reactive protein predict major adverse cardiovascular events in patients with stable coronary artery disease (from the Taichung CAD study).

Pan HC, Sheu WH, Lee WJ, Lee WL, Liao YC, Wang KY, Lee IT, Wang JS, Liang KW.

Clin Chim Acta. 2015 May 20;445:93-100. doi: 10.1016/j.cca.2015.03.029.

PMID:
25818243
13.

C-reactive protein and coronary artery disease.

Auer J, Berent R, Lassnig E, Eber B.

Jpn Heart J. 2002 Nov;43(6):607-19.

14.

Serum amyloid A as a predictor of coronary artery disease and cardiovascular outcome in women: the National Heart, Lung, and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation (WISE).

Johnson BD, Kip KE, Marroquin OC, Ridker PM, Kelsey SF, Shaw LJ, Pepine CJ, Sharaf B, Bairey Merz CN, Sopko G, Olson MB, Reis SE; National Heart, Lung, and Blood Institute..

Circulation. 2004 Feb 17;109(6):726-32.

15.

Predictor of event-free survival in patients with myocardial infarction.

Henareh L, Berglund M.

Acute Card Care. 2012 Sep;14(3):105-9. doi: 10.3109/17482941.2012.712142.

PMID:
22934967
16.

Preprocedural high-sensitivity C-reactive protein predicts death or myocardial infarction but not target vessel revascularization or stent thrombosis after percutaneous coronary intervention.

Delhaye C, Sudre A, Lemesle G, Maréchaux S, Broucqsault D, Hennache B, Bauters C, Lablanche JM.

Cardiovasc Revasc Med. 2009 Jul-Sep;10(3):144-50. doi: 10.1016/j.carrev.2009.01.005.

PMID:
19595394
17.
18.

Preprocedural C-reactive protein is not associated with angiographic restenosis or target lesion revascularization after coronary artery stent placement.

Rittersma SZ, de Winter RJ, Koch KT, Schotborgh CE, Bax M, Heyde GS, van Straalen JP, Mulder KJ, Tijssen JG, Sanders GT, Piek JJ.

Clin Chem. 2004 Sep;50(9):1589-96.

19.

Prognostic utility of lipoprotein-associated phospholipase A2 for cardiovascular outcomes in patients with stable coronary artery disease.

Sabatine MS, Morrow DA, O'Donoghue M, Jablonksi KA, Rice MM, Solomon S, Rosenberg Y, Domanski MJ, Hsia J; PEACE Investigators..

Arterioscler Thromb Vasc Biol. 2007 Nov;27(11):2463-9.

20.

Clinical characteristics, cardiac events and coronary angiographic findings in the prospective PREVEND cohort: an observational study.

Geluk CA, Tio RA, Tijssen JG, van Dijk RB, Dijk WA, Hillege HL, de Jong PE, van Gilst WH, Zijlstra F.

Neth Heart J. 2007;15(4):133-41.

Supplemental Content

Support Center